Recent global health developments highlight emerging disease threats, shifting corporate pharmaceutical strategies, and access challenges in specialized medical treatments.

Health officials in Pennsylvania confirmed two measles-related deaths, marking the first U.S. fatalities from the disease reported in 2026.

A record-breaking Salmonella outbreak linked to contaminated eggs has infected at least 306 individuals in Belgium, according to national food safety authorities.

Approximately 14% of U.S. employers plan to drop coverage for weight-loss drugs like GLP-1 agonists by 2027 due to the burden of rising healthcare costs.

Bristol Myers Squibb has officially terminated its manufacturing partnership with cell therapy startup Cellares regarding the development of personalized blood cancer treatments.

Moderna and Merck continue to advance their personalized mRNA cancer vaccine, though researchers warn that significant logistical and manufacturing barriers remain before widespread clinical adoption.

Disruptions to the PEPFAR program in 2025 have prompted warnings of over 500,000 potential new HIV infections and threats to global health security.

A new study reveals that early treatment with the triple therapy elexacaftor-tezacaftor-ivacaftor significantly improves olfactory function in young children diagnosed with cystic fibrosis.

Research across 10 U.S. health systems indicates significant geographic, age, and sex-based disparities in the administration of Meningococcal B vaccines for high-risk youth populations.